Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6228670 | 1.00 | ALDH1A1 (0.46) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL6653970 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL6653966 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL457159 | 0.73 | CYP11B1 (0.61) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL457158 | 0.73 | CYP11B1 (0.61) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL29881470 | 0.73 | CYP11B1 (0.61) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL193843 | 0.73 | — | — | |
| SCHEMBL1431431 | 0.72 | ALDH1A1 (0.39) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL18255045 | 0.72 | ALDH1A1 (0.39) | ALDH1A1TRPA1LMNAALOX5MAPK1 | |
| SCHEMBL21421414 | 0.72 | ALDH1A1 (0.39) | ALDH1A1TRPA1LMNAALOX5MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | claimed |
| CN-100351240-C | Rosuvastatin calcium synthesis method | ANHUI QINGYUN MEDICINAL CHEMIC (CN) | 2007-11-28 | — | — | CN | claimed |
| CN-1807418-A | Rosuvastatin calcium synthesis method | ANHUI QINGYUN MEDICINAL CHEMIC (CN) | 2006-07-26 | — | — | CN | claimed |
| CN-110248934-B | Heteroaryl PAD4 inhibitors | 帕德罗科治疗公司 | 2022-05-24 | — | — | CN | disclosed |
| US-8049010-B2 | Using 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-formaldehyde as raw material; cyanation to 4-4'-fluorophenyl-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidine-5-acrylonitrile; carbonylation, chain extension, hydrolysis, neutralization, decomposition, catalysis | Anhui Qingyun Pharmaceuticals & Chemical Co., Ltd. (CN) | 2011-11-01 | — | — | US | disclosed |
| CN-100351240-C | Rosuvastatin calcium synthesis method | ANHUI QINGYUN MEDICINAL CHEMIC (CN) | 2007-11-28 | — | — | CN | disclosed |
| CN-1807418-A | Rosuvastatin calcium synthesis method | ANHUI QINGYUN MEDICINAL CHEMIC (CN) | 2006-07-26 | — | — | CN | disclosed |
| CN-1671726-A | 3-descladinosyl-6-O-carbamoyl and 6-O-alkoxycarbonyl macrolide antibacterial agents | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-21 | — | — | CN | disclosed |
| EP-1513856-A1 | 3-DESCLADINOSYL-6-O-CARBAMOYL AND 6-O-CARBONOYL MACROLIDE ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-16 | — | — | EP | disclosed |
| US-6825172-B2 | BACTERICIDES; AGAINST GRAMNEGATIVE, GRAMPOSITIVE BACTERIA | JANSSEN PHARMACEUTICA, NV (BE) | 2004-11-30 | — | — | US | disclosed |
| US-20040018994-A1 | 3-Descladinosyl-6-O-carbamoyl and 6-O-carbonoyl macrolide antibacterial agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003102010-A1 | 3-DESCLADINOSYL-6-O-CARBAMOYL AND 6-O-CARBONOYL MACROLIDE ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018994-A1 | 3-Descladinosyl-6-O-carbamoyl and 6-O-carbonoyl macrolide antibacterial agents | CHCHD6, MRPL21, MRPS18B | ALDH1A1 4053/4885TRPA1 4718/4885LMNA 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.